Detection of recurrent disease is essential for treatment planning in patients with paraganglioma. The aim of this study was to compare 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy [whole-body and single-photon emission computed tomography (SPECT) computed tomography (CT) scanning] and fluorine-18-L-dihydroxyphenylalanine positron emission tomography CT (18F-DOPA PET-CT) in the re-staging of patients with known or suspected recurrent paraganglioma.
Rufini, V., Treglia, G., Castaldi, P., Perotti, G., Calcagni, M. L., Corsello, S. M., Galli, G., Fanti, S., Giordano, A., Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma, <<NUCLEAR MEDICINE COMMUNICATIONS>>, 2011; 32 (7): 575-582. [doi:10.1097/MNM.0b013e328345a340] [http://hdl.handle.net/10807/5498]
Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma
Rufini, Vittoria;Treglia, Giorgio;Castaldi, Paola;Perotti, Germano;Calcagni, Maria Lucia;Corsello, Salvatore Maria;Giordano, Aldo
2011
Abstract
Detection of recurrent disease is essential for treatment planning in patients with paraganglioma. The aim of this study was to compare 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy [whole-body and single-photon emission computed tomography (SPECT) computed tomography (CT) scanning] and fluorine-18-L-dihydroxyphenylalanine positron emission tomography CT (18F-DOPA PET-CT) in the re-staging of patients with known or suspected recurrent paraganglioma.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
